Nanotechnology Core

    It is the mission of the Vaccine Delivery/Nanotechnology Core facility to support and advance vaccine research capacity by providing novel and innovative vaccine delivery formulations. The major goal of the Core, located at Xavier University, is to maintain a state-of-the-art innovative polymeric vaccine delivery research facility in order to support inter-disciplinary research.
    Core personnel will provide leadership in planning, designing, and implementing innovative nanotechnology and will also assist investigators in conducting pre-formulation and formulation studies of any potential novel vaccine delivery system for preclinical and NDA studies (New Drug Application following USFDA guidelines).
    Nano-delivery technology will be developed and/or adapted, in collaboration with LVC/SLIIDR researchers, to address the special requirements of either systemic or mucosal (ie. intranasal, pulmonary, oral, or intra-vaginal) particle-mediated delivery of peptides, proteins and/or recombinant DNA vaccines in preclinical and, ultimately, clinical studies.
    Targeted particle- or lipid-mediated delivery either of proteins via novel routes (eg. transcutaneous) or of alternative recombinant vaccine vectors is already under development in the Core and this technology will also be made available to other LVC/SLIIDR investigators.
    Currently, the NIH-funded nanotechnology research laboratory is equipped with R&D-scale pharmaceutical formulation equipment, with research staff who have developed unique skills in micro-encapsulation for controlled release.

Location:

Xavier University